Business, energy, technology, markets and global industry news from Business News Today

Corcept Therapeutics

PharmaDeviceNews Corcept Therapeutics
Corcept Therapeutics’ second-quarter results will put early Lifyorli launch momentum, Korlym growth and the relacorilant FDA review under close scrutiny. Representative image.
Pharma & Biotech

Corcept Therapeutics sets July 29 Q2 call as Lifyorli launch and relacorilant review take centre stage

Corcept Therapeutics will report Q2 results on July 29, with Lifyorli launch sales, Korlym growth and relacorilant’s FDA review in focus.

Read More
Representative image: Corcept Therapeutics’ dazucorilant survival signal in amyotrophic lateral sclerosis highlights how ALS clinical trials are shifting attention from short-term functional scores to longer-term survival outcomes.
Pharma & Biotech

A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?

A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.

Read More
Pharma & Biotech

ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice

Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.

Read More
Medical Devices & Diagnostics

Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial

Corcept's MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.

Read More